Towards Early diagnosis and biomarker validation in Arthritis Management (EuroTEAM)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: European Comission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe


The Towards Early diagnosis and biomarker validation in Arthritis Management (EuroTEAM) project has been funded by the European Union for four years, starting in November 2012. Through EuroTEAM, approaches will be developed to predict the onset of rheumatoid arthritis (RA) in people who do not yet have the disease. Ultimately, this will help in the development of treatments to prevent people from getting RA in the first place.


EuroTEAM’s key objective is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to RA. The project will achieve this objective by developing a collaborative, integrated program of work that links researchers with key small to medium-sized enterprises (SMEs) involved in biomarker development to produce a “personalized predictive bioprofile” for patients destined to develop RA.

EuroTEAM will deliver a step change in the development of biomarkers and diagnostic kits that are timely and strategically important for European SMEs and are based on a disease (RA) in which concrete genetic and environmental risk factors have already been established.

EuroTEAM will do the following:

Consortium History

November 2012: Project start
February 2016: Final EuroTEAM annual meeting

Structure & Governance

Together, the partners will contribute to five work packages (WPs):
WP1: Genetic biomarkers
WP2: Blood-based biomarkers
WP3: Tissue-based biomarkers
WP4: Dissemination and user integration
WP5: Project management


The project will be funded for four years. The European Commission contribution will be €5.8 million.

Patient Engagement

A small group of patient research partners (PRPs), from all over Europe, will also participate in the project.

The PRPs will be PARE (People with Arthritis/Rheumatism in Europe) board members and founders/ members of national rheumatic and RA patient organizations. Their involvement will be crucial and will provide the academic and industry partners with feedback on the research work carried out by the project and with insight into the experiences of RA patients.

Points of Contact

Health Sciences Research Centre, room 107a
University of Birmingham
West Midlands, UK
B15 2TT
phone: +44 (0) 121 414 9249
email: (Becky Birch, Project Manager)

Sponsors & Partners

Athrogen BV

Charite – Universitatscmedizin Berlin

deCODE (Islensk Erfdagreining EHF)

Kungliga Teniska Hogskolan

Leids Universitair Medisch Centrum

Medizinische Universitat Wien

ORGENTEC Diagnostika GmbH

Universitat Zurich

Universitatsklinikum Erlangen

University of Birmingham

University of Glasgow

University of Leeds

University of Manchester

 Uppsala Universitet

Last Updated: 04/07/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.